Skip to content

03759.HK

Pharmaron Beijing Co., Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 29.52
+0.48%
Ask drillr

Year over year

Reported trailing growth

Revenue
+15.0%
EBITDA
+23.6%
EBIT
+23.7%
EPS
+21.5%
Free cash flow
+265.9%
Operating cash flow
+33.2%

Forward estimates

Based on analyst estimates

Revenue
+15.8%
EBITDA
+101.6%
EPS
+56.9%

Three-year CAGR

Revenue
+11.1%
EBITDA
+9.1%
EBIT
+4.5%
Net income
+6.6%
EPS
+1.5%
Free cash flow
+3.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026